TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06283719: A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Stu

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 265 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06283719 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06283719 Rescue Dossier →